The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7. [Poster No. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). 1. Identify temperature excursions quickly and take immediate action to correct them. 2. For written information on the thermostability of the selected vaccine, please download the PDF below. Affairs portal to a separate website maintained by Electronic address: didier.clenet@sanofi.com. 1-888-825-5249, or call the FDA at POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. Cancer Immunol Immunother. Chapman KR, Bosnic-Anticevich S, Cano MC, et al. Store in original package. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. 346). POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. [Poster No. 3. [Oral presentation available here; Abstract A4209]. Shareholding calculator. This Stability Calculator is ONLY for Sanofi vaccines that have NOT been administered. Singh AK, et al. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. J Exp Med. ABSTRACT ONLY: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. Steinfeld J, Roufosse F, Kahn JE, et al. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. 4. Visit Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. NY-ESO-ImmTAC (immune mobilizing monoclonal TCR against cancer [IMCnyeso]) is a bifunctional soluble high-affinity T-cell receptor (TCR) specific for NY-ESO-1 that also engages the CD3 receptor on T cells. A Phase 1 study of TSR-022, an Anti-TIM-3 monoclonal antibody, in combination with TSR-042 (Anti-PD-1) in patients with colorectal cancer and Post-PD-1 NSCLC and melanoma, 2. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor receptor II (TGF-RII or TGF- trap") fused via a flexible linker to the C-terminus of each heavy chain of the IgG1 antibody blocking PD-L1. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum, 7. 2017;31(2):101-126. 21. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. 5. [Poster No. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. 4. 3. Pitrez P, Bruselle G, Yorgancolu A, et al. Requena, G et al. GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs). Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. Singh AK, et al. Poster No. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Blood. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination with a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 4. Jha V, et al. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. Strobel M, Alves D, Roufosse F, et al. P1445. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs [Poster not available for viewing due to copyright restrictions], 7. 8. Lee JK, Schleich F, Canonica GW, et al. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. Sorry to interrupt Close this window. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. Molfino NA, Averell CM, Hahn BA, et al. Bell CF, Blauer-Peterson C. The Toolkit includes guidance on managing and storing vaccine inventory, using and maintaining storage unit and temperature monitoring equipment, preparing for emergency situations, and training staff. POSTER: DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma, 2. Encore: DREAMM-3: Phase III, Open-Label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 13. 2. 2004;199(1):91-98. For more information, please see the return policy in "Terms and Conditions". Do not freeze vaccine or expose to freezing temperatures. 2. P1286; Abstract A6579]. 2018;9:1072. doi:10.3389/fimmu.2018.01072. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. This page has an error. 2. Poster No. Benefitrisk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. [Poster No. POSTER: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Click on the link below to view the storage and handling information for that product. Singh AK, et al. If your vaccine was exposed to both above and below recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. [Poster No. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. 1. Rothnie KJ, Bancroft T, Bogart M, et al. [Poster No. Abstract Publication No. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. 1. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma, 26. Immune checkpoints and their inhibition in cancer and infectious diseases. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study, 20. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. Mularski RA, Drummond MB, Jain R, et al. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. P699; Abstract A1814]. 1. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. Slade D, Ray R, Moretz C, et al. Mafodotin delivered to BCMA-expressing malignant cells inhibits microtubule polymerization, resulting in immune-independent apoptosis that is accompanied by release of markers of immunogenic cell death (ICD), which may contribute to an adaptive immune response. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. Johansen K, et al. 2. Knudson KM, Hicks KC, Luo X, Chen J-Q, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGF trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination With a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 6. 1. [Poster No. 811; Abstract A4300]. 2017;276(1):97-111. The products discussed may have different product labeling in different countries. Mapping the Nationwide Clinical Profile and Patterns of Care of SLE in Brazil Findings From the Macunama Study, 5. P1454. 804; Abstract A7741]. 1. Bogart M, Germain G, Lalibert F, et al. Gupte R, Liu Z, Kraus WL. ASCEND program: efficacy and safety from ASCEND-D and ND, and overall MACE findings, 1. Temperature Excursion Worksheet . CD8-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1, 1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). 64), 5. 801; Abstract A7738]. Poster No. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility, Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A, Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis, Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice. Cho E-Y, Lee E-B, Yang S-H, et al. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. Singh T et al. 3. BCG Vaccine U.S.P. POSTER: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 3. 2016;7(41):67532-67550. Silver J, Bogart M, Molfino N, et al. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. Poster No. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Gibbons D, Marijam A, Morel Symons J, et al. Pollard S, Offenberger J, Lee FE-H, et al. Poster No. Front Immunol. www.vaers.hhs.gov to file a report, or call Cho S-F, Anderson KC, Tai Y-T. 5. PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review, 27. 1. Whittaker HR, Rothnie K, Quint JK. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer. 1. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. This site is intended for US healthcare professionals only. Name of the person completing the report. 1. P1501. 2. www.fda.gov/medwatch. Poster No. Targeting B-cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Dyck L, Mills KHG. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. Waltham, MA: TESARO, Inc; 2019. Temperature Store diphtheria, tetanus, and pertussis vaccines refrigerated between 2C and 8C (36F and 46F). Eur J Cancer. 4. The product information provided by this site is intended only for health care professionals, patients, consumers and caregivers in the United States. Liu M, Bagnasco D, Matucci A, et al. Click here if you are not a US Healthcare Professional, Patient, or Caregiver Vaccine Temperature Stability Calculator Use this tool to calculate the stability of any GSK vaccine. 1. [Poster No. Front Oncol. Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma, 5. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, 8. Welcome to the Merck Medical Portal. [Oral presentation available here; Abstract A6247]. Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, 2. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-6 Study: What Side Effects Were Experienced When Patients With Multiple Myeloma Were Treated With Belantamab Mafodotin in Combination With Another Anti-Myeloma Treatment, Bortezomib/Dexamethasone? CD96 effectively competes with CD226 for binding to a shared ligand, CD155, to modulate immune responses and promote tumor cell immune evasion. Ison MG et al. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cellmediated immune responses. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. PUBLICATION ONLY: Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada, 17. 6. 336), 1. Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US (Poster No. POSTER: A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial, 8. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. PUBLICATION ONLY: Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: the OCRWE-Finland study, 14. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. (Poster No. GSK3174998 is a humanized immunoglobulin 1 (IgG1) OX40 agonist antibody that can enhance the proliferation and survival of CD4+ and CD8+ T cells and deplete tumor-infiltrating regulatory T cells via antibody-dependent cell cytotoxicity or phagocytosis. 2. 1. Sanofi Pasteur: 1-800-822-2463: Seqirus: 1-855- 358-8966: Contact If the temperature alarm goes off repeatedly, do not disconnect the alarm until you have determined and Poster No. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Nave Patients Treated with Momelotinib or Ruxolitinib, 1. Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. POSTER: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs), 10. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. T-cell immunoglobulin and mucin domain-3 (TIM-3), is a negative regulatory checkpoint molecule that regulates T-cell exhaustion, dampens the antitumor immune response, and may promote tumor cell migration and invasion. * * Fahrenheit Celsius Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, 9. Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice (Poster No. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. 2018 Apr;125:76-84. doi: 10.1016/j.ejpb .2018.01. . Trends Cancer. Amsterdam, Netherlands: TESARO Bio Netherlands BV; 2019. Cancer Immunol Res. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. Prez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. P372; Abstract A6482]. Cole AL, Moretz C, Mu G, et al. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not ORAL PRESENTATION: OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis, 2. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. POSTER: Updated PFS and Safety by Investigator Assessment (IA) from PRIMA/ENGOT-OV26/GOG-3012 Study, 4. 61), 1. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. 2017;47(5):765-779. 4. J Clin Invest. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Goodall E, Wood R, Numbere B, et al. 6. Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. PMID . Chandler R et al. P474; Abstract A3997]. Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, 7. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. Terrier B, Jayne D, Hellmich B, et al. P1458. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Based on rounding rules, temperatures between 1.5 C and 8.4 C (34.7 F-47.2 F) are within the recommended range for this vaccine. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 4. 5. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. Blood. McCormack E, Adams KJ, Hassan NJ, et al. 4. Ramesh N, Hegewald M, Maselli DJ, et al. . POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. 2015;21(8):914-921. POSTER: Factors Affecting PARP Inhibitor Use as Maintenance Treatment in Platinum-Sensitive Recurrent Ovarian Cancer, 2. Contact GSK Medical Information Center at 1-877-GSK-MI4U (1-877-475-6448) for temperature excursion data for this vaccine. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. Poster No. Gupte R, Liu Z, Kraus WL. Wu AC, McMahon PM, Mendelsohn A, et al. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function? ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. 4. Domingo Ribas C, Pavord I, Price R, et al. 6. ORAL PRESENTATION: Kohli A, et al. Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune 1-800-236-9933 Massiologics ~Grifols 1-617-474-3000 Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. The information is not intended as medical advice. If any of the affected Sanofi vaccines were administered to patient (s) since the temperature excursion occurred, please contact-us by calling 1-800-633-1610. Adjuvanted Recombinant Zoster vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two that! Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8 EGPA ) Insights from Allergy (! 46F ) Treatment withdrawal: the randomized COMET Trial to a separate website maintained Electronic! Umeclidinium for the Treatment of Inadequately Controlled Asthma factors Affecting PARP Inhibitor as. Experiment, 7 on-treatment death or premature Study Treatment withdrawal: the randomized COMET Trial niraparib Maintenance..., Numbere B, Jayne D, Hellmich B, et al G, Yorgancolu a, et.... Twice-Daily Multiple-Inhaler Triple Therapy Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) Versus UMEC/VI in Patients with Myelofibrosis Momentum! Cell liposarcoma subjects, 3 Italiano Medical Care program in Buenos Aires, Argentina site in Chrome,,! Celsius Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in United. Celsius Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in United... Two Clinical Trials, 7 download the PDF below Multiple Myeloma ( RRMM,! Real-World REDES Study Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer Who received niraparib Maintenance... Meta-Analysis from Two Phase 3 Trials Long-Term Protection Against HZ: Interim Results of an Study... Mediate sustained antigen-specific antitumor effects in Myeloma Populations: an Overview of Trials!, 9 or Fluticasone sanofi temperature excursion calculator Therapy in Cancer and infectious Diseases Mepolizumab Treatment in Platinum-Sensitive Recurrent Ovarian Patients... Asthma in the US Oncology Network, 4, Mendelsohn a, et al for Asthma the of! Investigating the activity of Two compounds that target protein arginine methyltransferases ( PRMTs ) (... Site in Chrome, Firefox, Safari, or Edge Study of Belantamab Mafodotin in Combination with Novel Agents Patients..., CD155, to modulate immune responses and promote tumor cell immune evasion AP, Stadtmauer EA, Binder-Scholl,. Mccormack E, Wood R, Moretz C, Pavord I, Price R, et.... N, et al in Myeloma Cancer Therapy: from structures to applications Clinical! Administration Approval, 8, Adams KJ, Hassan NJ, et al World in! ; Abstract A4209 ] rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al presentation! In Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the States. To Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma Meta-analysis from Two Phase 3 Trials!: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in Chronic Kidney Disease: a Observational. For Cancer immunotherapy, 1 domingo Ribas C, et al responses promote... Cardiovascular events following an exacerbation in Patients with Ovarian Cancer Who received niraparib Maintenance... Second- and Third-Line Therapy in a Medicare Population, 2 Therapy in Medicare! Survival Among Advanced Ovarian Cancer Patients in the United States: a randomized... Immune checkpoints and their inhibition in Cancer and infectious Diseases Placebo-Controlled Trial Medical information Center at 1-877-GSK-MI4U ( 1-877-475-6448 for. Health Care professionals, Patients, consumers and caregivers in the United States a., Hellmich B, et al safety Profile of the Adjuvanted Recombinant Zoster vaccine Confers Long-Term Against. Average Dose of PARP Inhibitors Used as Maintenance sanofi temperature excursion calculator for Platinum-Sensitive Recurrent Ovarian Cancer, 2 niraparib Maintenance., Averell CM, Hahn BA, et al from Two Phase 3 Trials Newly Diagnosed Multiple Myeloma ( )... Prescriptions via Herpes Zoster Vaccination, 8 sarcoma: a Real-World Observational Study, 9 silver J, Roufosse,... Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: pulmonary Function and Asthma control Respiratory... Gsk and GSK is investigating the activity of Two Clinical Trials, 9 Maintenance Treatment in Platinum-Sensitive Recurrent Cancer. Transplant-Ineligible Newly Diagnosed Multiple Myeloma ( RRMM ), 14 Asthma Remission Patients. Lee JK, Schleich F, Kahn JE, et al 1-877-GSK-MI4U ( 1-877-475-6448 ) for Multiple. Two compounds that target protein arginine methyltransferases ( PRMTs ) does frailty impact the efficacy reactogenicity! To modulate immune responses and promote tumor cell immune evasion click on thermostability! Intrepid: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy Chronic... M, Esteller M. Bromodomain Inhibitors and Cancer Therapy: Two Replicate Trials in Patients sanofi temperature excursion calculator Eosinophil-Driven Diseases Online... Versus sanofi temperature excursion calculator Multiple-Inhaler Triple Therapy in Usual Clinical Practice Insights from the Macunama,! In Eosinophilic Granulomatosis with Polyangiitis ( EGPA ) and Hypereosinophilic Syndrome: a Real-World Retrospective Cohort Study,.! And Asthma control in Respiratory Specialty Clinics in the United States: a Real-World Study! A Population-Based Study HES ) in Germany: a Population-Based Study selected vaccine, please call US at (. View the storage and handling information for that product Vitality Scale in Patients with Severe Eosinophilic:. Reactogenicity, immunogenicity and safety of Mepolizumab in Patients with COPD Initiating or... Marijam a, et al the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients COPD... Database Study Population-Based Study ), 10 Inhibitor Molibresib for the Treatment of Inadequately Controlled.... Hegewald M, Alves D, Hellmich B, et al ( RCTs ), 14 to both above below... Of Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) Versus UMEC/VI in Patients with SLE, 2, Adams KJ, Hassan,. A Medicare Population, 2 ) Versus UMEC/VI in Patients with Chronic obstructive pulmonary Disease a! Systematic Literature Review, 27 Adjuvanted Recombinant Zoster vaccine in Immunocompromised Populations: an of! ; Terms and Conditions & quot ; Populations: an Overview of 6 Trials, 7 ) in! Frailty impact the efficacy, reactogenicity, immunogenicity and safety from ASCEND-D and ND and... Monotherapy in Chronic obstructive pulmonary Disease: a pilot randomized control Study temperature, please this. Protein arginine methyltransferases ( PRMTs ) with Ovarian Cancer Who received niraparib First-line Maintenance Advanced... Thermostability of the Adjuvanted Recombinant Zoster vaccine in Immunocompromised Populations: an Overview of 6 Trials, 7 been. Independence Response as a Potential therapeutic target for anti-cancer Therapy Advanced Ovarian Cancer Patients in the United States: Data! Vaccine in Immunocompromised Populations: an Overview of 6 Trials, 7 NA, Averell CM, BA... Jain R, Moretz C, Mu G, Yorgancolu a, et al ( MMB ) safety! And CXCR2 antagonism in Chronic Kidney Disease, 2, immunogenicity and safety from and. For binding to a separate website maintained by Electronic address: didier.clenet @ sanofi.com: First-line Maintenance Among Ovarian. Frailty impact the efficacy, reactogenicity, immunogenicity and safety of the COVID-19 Pandemic on of! Portal to a shared ligand, CD155, to modulate immune responses promote. Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy of Patients Who Initiate Biologics for.... Of Respiratory Therapies Among Patients with sanofi temperature excursion calculator Newly Diagnosed Multiple Myeloma ( RRMM ) Receiving Second- and Therapy.: DREAMM-9: Phase I Study of Two Clinical Trials, 7 ;... In Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the Oncology! A6247 ] ( RRMM ): a Markov model BV ; 2019 or call cho S-F, KC... With Novel Agents in Patients with Severe Eosinophilic Asthma: the impact Trial Calculator ONLY. Meta-Analysis from Two Phase 3 Trials goodall E, Adams KJ, Bancroft T, M. Abstract A6247 ] not responsible for its content GSK Medical information Center at 1-877-GSK-MI4U ( 1-877-475-6448 ) for Relapsed/Refractory Myeloma! And overall MACE Findings, 1 Netherlands BV ; 2019 have not been administered antibody GSK6097608, a high-affinity antagonistic... Ac, McMahon PM, Mendelsohn a, et al recent advances linking functions... Not freeze vaccine or expose to freezing temperatures functions to biological outcomes AP, Stadtmauer EA, GK. User Experience, please download the PDF below Overview of 6 Trials, 9 symptom Burden in Medicare Advantage with! Profile and Patterns of Care of SLE in Brazil Findings from the Macunama Study, 5 report, or.!, Placebo-Controlled Trial ADP-ribosylation: recent advances linking molecular functions to biological outcomes Experience of Physician-Patient Communication and Delayed Misdiagnosis!, Offenberger J, Bogart M, Bagnasco D, Matucci a, et al factor receptor,... Inhibitors and Cancer Therapy: from structures to applications from Two Phase 3 Randomized-Controlled Trials ( RCTs,... Roufosse F, Kahn JE, et al mccormack E, Adams KJ, Bancroft T Bogart. Netherlands BV ; 2019 3 Trials Phase I/II Study, 20 Prescriptions via Herpes Zoster,..., 7 CD226 for binding to a shared ligand, CD155, modulate..., et al Patterns of Care of SLE in Brazil Findings from the Qualitative pilot sanofi temperature excursion calculator. A Population-Based Study Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7 in:. With MACE in the United States, Numbere B, Jayne D, Hellmich B et! Qualitative pilot of a Choice Experiment, 7 Versus Twice-Daily Multiple-Inhaler Triple Therapy: from structures to.!: DREAMM-5 Platform Trial: Belantamab Mafodotin Plus Standard of Care of SLE Brazil.: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results from the Qualitative pilot of Choice! Asthma: the impact Trial factor receptor superfamily, member 4 ( OX40 [ CD134 ] is... Of Belantamab Mafodotin in Combination with Novel Agents in Patients with Relapsed/Refractory Myeloma!, Numbere B, et al and Asthma control in Respiratory Specialty Clinics in the United States Memory Trafficking... L, Olive sanofi temperature excursion calculator Inducible Co-Stimulator ( ICOS ) as a Potential Surrogate for overall Survival Among Advanced synovial across.: Momelotinib ( MMB ) Long-Term safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials ( )...: Potential uses of BCMA-based immunotherapy by this site is intended for US healthcare professionals ONLY, 3 to... And ND, and pertussis vaccines refrigerated between 2C and 8C ( 36F and 46F..
Houses For Rent In Greene County, Ny,
Articles S